The Peptide Technology Platform was built by a senior team with more than 20 years of experience in peptide drug discovery and development. Our team has a proven ability to drive the entire drug development process, evidenced by more than 10 regulatory submissions, 6 production approvals, and over 60 patent applications. The platform comprises three major technology pillars: • Novatide Peptide Technology Platform • SupOraTide Oral Peptide Technology Platform • Longlastide Ultra-Long-Acting Peptide Technology Platform.

• NovaPeptide Technology Platform:

    Established in 1998, NovaPeptide is one of China's leading platforms specializing in industrial-scale         production of recombinant insulin analogs

    The insulin production line has passed EMA GMP inspection, ensuring a secure and tightly controlled         supply chain 

    Our commercial portfolio covers long-acting, rapid-acting, and premixed insulin formulations         marketed in more than 20 countries worldwide

    Fourth-generation once-weekly insulin candidates GZR4 and GZR101 are progressing through Phase 3     clinical trials; GZR4 has received IND clearance from the U.S. FDA 

    Enables multi-target synergistic metabolic regulation 

    Utilizes amino acid site-directed mutagenesis to enhance molecular bioactivity and stability 

    Employs mature fatty-acid chain conjugation technology to enhance albumin binding and extend half-    life 

    Expands the product pipeline and strengthens patent protection

• SupOraTide Oral Peptide Technology Platform 

    Improves oral bioavailability 

    Uses synergistic permeation-enhancing formulation technology 

    Focuses on once-weekly oral peptide formulations 

    Supports scalable implementation of oral peptide formulations

• Longlastide Ultra-Long-Acting Peptide Technology Platform 

    Long-acting technology for protein and peptide drugs 

    Excellent biocompatibility 

    Stable and controllable drug release 

    Reduces dosing frequency from weekly to monthly or quarterly 

    Compatible with a wide range of peptide drugs 

    Supports extension of product life cycles

To accelerate innovative peptide drug development, we have established an analytical platform that supports the full cycle of screening, characterization, and optimization. The platform enables efficient activity screening using a multi-functional microplate reader (Tecan Spark 20M) and provides precise molecular interaction analysis through a Biacore 8K. It supports detailed structural and purity characterization using multi-vendor chromatography systems, high-resolution MS, and CE-MS, and offers robust stability assessment using differential scanning calorimetry (DSC). This platform provides high-precision analytical support for rapid candidate identification and optimization, accelerating drug discovery and development.

High-Performance Liquid Chromatograph              Mass Spectrometer                               Biacore                          Differential Scanning Calorimeter